Tankeu Aurel T, Azabji-Kenfack Marcel, Nganou Chris-Nadège, Ngassam Eliane, Kuate-Mfeukeu Liliane, Mba Camille, Dehayem Mesmin Y, Mbanya Jean-Claude, Sobngwi Eugene
National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon.
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
BMC Res Notes. 2018 Feb 22;11(1):151. doi: 10.1186/s13104-018-3224-x.
We aimed to determine the effect of propanolol on heart rate variability (HRV) in hyperthyroidism before antithyroid treatment. This was a before and after study, on ten patients presenting overt hyperthyroidism naïve to treatment. In each patient, a resting electrocardiogram was done followed by estimation of cardiac autonomic dysfunction during five maneuvers (Ewing battery tests). Long term HRV measurement was done using 24 h ambulatory electrocardiographic recording. This automatically provided estimation of HRV using SDNN and RMSSD index, LF, HF, and HF/LF ratio. After baseline investigations, 40 mg of propanolol was given twice a day for 3 days and same parameters were measured after 72 h of treatment.
Our patients were aged 40 ± 10 years. Propanolol significantly reduced RR and HR interval (669 ms vs 763 ms and 91 vs 79 bpm; p < 0.01). QT and PR space were significantly extended (360 vs 384 ms and 133 vs 172 ms; p = 0.01). It increases QRS complex and blood pressure response to sustained handgrip but failed to modify previously decreased heart response to deep breathing. HRV parameters such as SDNN, RMSSD, LF, HF and sympathovagal balance estimate by HF/LF ratio remained unchanged. Although a significant reduction in heart excitability, propanolol failed to restore a good sympathovagal balance in hyperthyroidism. Trial registration NCT03393728 "Retrospectively registered".
我们旨在确定普萘洛尔对甲状腺功能亢进症患者在抗甲状腺治疗前心率变异性(HRV)的影响。这是一项前后对照研究,对象为10例未经治疗的显性甲状腺功能亢进症患者。对每位患者进行静息心电图检查,随后在五项操作(尤因电池测试)期间评估心脏自主神经功能障碍。使用24小时动态心电图记录进行长期HRV测量。这自动提供了使用SDNN和RMSSD指数、低频(LF)、高频(HF)以及HF/LF比值对HRV的评估。在进行基线检查后,每天两次给予40毫克普萘洛尔,共3天,并在治疗72小时后测量相同参数。
我们的患者年龄为40±10岁。普萘洛尔显著缩短RR和HR间期(669毫秒对763毫秒,91次/分对79次/分;p<0.01)。QT和PR间期显著延长(360毫秒对384毫秒,133毫秒对172毫秒;p = 0.01)。它增加了对持续握力的QRS波群和血压反应,但未能改变先前对深呼吸降低的心脏反应。HRV参数,如SDNN、RMSSD、LF、HF以及通过HF/LF比值评估的交感迷走神经平衡保持不变。尽管心脏兴奋性显著降低,但普萘洛尔未能恢复甲状腺功能亢进症患者良好的交感迷走神经平衡。试验注册号NCT03393728“回顾性注册”。